These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29901287)

  • 1. [Characteristic features of urinary calcium excretion and osteoporosis risk factors in patients with urolithiasis].
    Demidko LS; Rudenko VI; Grigoryan VA; Demidko YL; Enikeev ME; Inoyatov ZS; Amosova MV
    Urologiia; 2018 May; (2):5-8. PubMed ID: 29901287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inluence of osteoporosis and its causative factors on the prevention of recurrence of urinary stone disease].
    Demidko LS; Rudenko VI; Fadeev VV; Demidko YL; Amosov AV; Kuzmicheva GM; Grigoryan VA; Enikeev ME; Amosova MV
    Urologiia; 2019 Sep; (4):26-31. PubMed ID: 31535801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary risk factors for recurrent calcium stone formation in Thai stone formers.
    Stitchantrakul W; Kochakarn W; Ruangraksa C; Domrongkitchaiporn S
    J Med Assoc Thai; 2007 Apr; 90(4):688-98. PubMed ID: 17487123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical value of Canephron N after surgical treatment of urinary stone disease].
    Demidko YL; Rudenko VI; Grigoryan VA; Enikeev ME; Allenov SN; Kasiteridi IG; Ujegov TA; Amosov AV
    Urologiia; 2019 Jun; (2):15-20. PubMed ID: 31162895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mineralogical composition of urinary stones, risk factors and metabolic disturbances in patients with calcium-oxalate urolithiasis].
    Kustov AV; Strelnikov AI; Moryganov MA; Airapetyan AO; Smirnov PR; Lyalyakina EV; Toms SR
    Urologiia; 2017 Sep; (4):22-26. PubMed ID: 28952687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plant-derived terpenes in treating patients with urolithiasis].
    Alyaev YG; Rudenko VI; Perekalina AN; Kraev IG; Inoyatov ZS
    Urologiia; 2016 Apr; (2 Suppl 2):103-110. PubMed ID: 28247652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of recurrent urolithiasis in children is dependent on urinary calcium and citrate.
    DeFoor WR; Jackson E; Minevich E; Caillat A; Reddy P; Sheldon C; Asplin J
    Urology; 2010 Jul; 76(1):242-5. PubMed ID: 20110113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [DIAGNOSIS OF METABOLIC DISORDERS AND METAPHYLAXIS OF RECURRENT CALCIUM OXALATE UROLITHIASIS].
    Kustov AV; Strelnikov AL; Airapetyan AO; Moryganov MA; Zhuravleva NI
    Urologiia; 2015; (5):86-8. PubMed ID: 26859947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of overweight and obesity on the urinary excretion of promoters and inhibitors of stone formation in stone formers.
    Negri AL; Spivacow FR; Del Valle EE; Forrester M; Rosende G; Pinduli I
    Urol Res; 2008 Dec; 36(6):303-7. PubMed ID: 18985334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of urolithiasis in patients with intestinal fat malabsorption.
    Siener R; Petzold J; Bitterlich N; Alteheld B; Metzner C
    Urology; 2013 Jan; 81(1):17-24. PubMed ID: 23200965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Urinary citrate excretion in children with calcium urolithiasis].
    Sikora P; Bieniaś B; Majewski M; Borzecka H; Wawrzyszuk M; Zajaczkowska M
    Przegl Lek; 2006; 63 Suppl 3():134-6. PubMed ID: 16898511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid in the management of hypercalciuric stone formers.
    Ortiz-Alvarado O; Miyaoka R; Kriedberg C; Leavitt DA; Moeding A; Stessman M; Monga M
    Urology; 2012 Feb; 79(2):282-6. PubMed ID: 22000931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic assessment of recurrent and first renal calcium oxalate stone formers.
    Çakıroğlu B; Eyyupoğlu E; Hazar AI; Uyanik BS; Nuhoğlu B
    Arch Ital Urol Androl; 2016 Jul; 88(2):101-5. PubMed ID: 27377084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Urinary factors for calcium urolithiasis and their correction].
    Gaibullaev AA; Kariev SS
    Urologiia; 2018 Oct; (4):19-23. PubMed ID: 30761785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing urinary calcium excretion after ceftriaxone and cephalothin therapy in adults: possible association with urolithiasis.
    Otunctemur A; Ozbek E; Polat EC; Cekmen M; Dursun M; Cakir SS
    Urolithiasis; 2014 Apr; 42(2):105-8. PubMed ID: 24310104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium oxalate urolithiasis in children: urinary promoters/inhibitors and role of their ratios.
    Turudic D; Batinic D; Golubic AT; Lovric M; Milosevic D
    Eur J Pediatr; 2016 Dec; 175(12):1959-1965. PubMed ID: 27730307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New therapy using bisphosphonate for urolithiasis].
    Yasui T; Niimi K; Hirose M
    Clin Calcium; 2011 Oct; 21(10):1511-5. PubMed ID: 21960237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of potassium chloride and bicarbonate on thiazide-induced reduction in urinary calcium excretion.
    Frassetto LA; Nash E; Morris RC; Sebastian A
    Kidney Int; 2000 Aug; 58(2):748-52. PubMed ID: 10916098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urolithiasis and osteoporosis: clinical relevance and therapeutic implications.
    Bilić-Curcić I; Milas-Ahić J; Smolić M; Smolić R; Mihaljević I; Tucak-Zorić S
    Coll Antropol; 2009 Dec; 33 Suppl 2():189-92. PubMed ID: 20120412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lithogenic risk in patients from Paraguay with urolithiasis].
    Funes P; Echagüe G; Ruiz I; Rivas L; Zenteno J; Guillén R
    Rev Med Chil; 2016 Jun; 144(6):716-22. PubMed ID: 27598490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.